CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
Onco News
Pneumobase.it

Search results for "Eliquis"

New interim findings from a phase 2 proof-of-concept study of an investigational factor Xa inhibitor antidote, Andexanet alfa, in healthy volunteers who received the factor Xa inhibitor Apixaban ( Eli ...


Apixaban ( Eliquis ), an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism.In the randomized, double-blind study ( AMPLIFY ), researchers have ...


Bristol-Myers Squibb ( BMS ) and Pfizer have announced results of a pre-specified subanalysis of the phase 3 ARISTOTLE trial in relation to patient age. ARISTOTLE was designed to evaluate the effica ...


Results of a pre-specified secondary analysis of the Eliquis Phase 3 AMPLIFY-EXT trial ( Apixaban after the initial Management ofPuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXT ...


The coagulation system contributes greatly to the evolution of myocardial infarction ( MI ). Anticoagulation may reduce the occurrence of myocardial infarction as monotherapy or with concomitant use o ...


Amiodarone ( Cordarone ) is an effective medication in preventing atrial fibrillation ( AF ), but it interferes with the metabolism of Warfarin ( Coumadin ). A study has examined the association of ...


The new oral anticoagulants ( NOACs ) Dabigatran etexilate ( Pradaxa ), Rivaroxaban ( Xarelto ), and Apixaban ( Eliquis ) show similar efficacy for stroke prevention in patients with atrial fibrillati ...


The results from two analyses of the GLORIA-AF Registry Program examining the use of antithrombotic treatment to reduce the risk of stroke for patients with non-valvular atrial fibrillation ( NVAF ) w ...


A study has compared efficacy and safety among novel oral anticoagulants ( NOACs ), which have not been directly compared in randomized control trials to date. Investigators performed network meta- ...


In the Apixaban for Prevention of Acute Ischemic Events ( APPRAISE-2 ) trial, the use of Apixaban ( Eliquis ), when compared with placebo, in high-risk patients with a recent acute coronary syndrome ( ...


Apixaban ( Eliquis ), a direct factor Xa inhibitor approved for thromboembolic prophylaxis in patients with non-valvular atrial fibrillation, is increasingly used in patients undergoing catheter ablat ...


History of bleeding strongly influences decisions for anticoagulation in atrial fibrillation. Researchers have analyzed outcomes in relation to history of bleeding and randomization in ARISTOTLE trial ...


Historically, Warfarin ( Coumadin ) or Acetylsalicylic acid ( Aspirin ) have been the recommended therapeutic options for the extended treatment ( more than 3 months ) of venous thromboembolism ( VTE ...


In addition to Warfarin ( Coumadin ), there are four non-vitamin K antagonist oral anticoagulants ( NOACs ) available for stroke prevention in non-valvular atrial fibrillation ( NVAF ). There are li ...


Findings from a real-world data analysis of the U.S. Medicare database comparing the risk of stroke or systemic embolism and rate of major bleeding among patients with non-valvular atrial fibrillation ...